D'Ambra Vincenzo, Ricci Claudio, Ingaldi Carlo, Alberici Laura, Casadei Riccardo
Division of Pancreatic Surgery, IRCCS, Azienda Ospedaliero Universitaria Di Bologna, Via Massarenti N.9, 40138, Bologna, Italy.
Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, S. Orsola-Malpighi Hospital, Via Massarenti N.9, 40138, Bologna, Italy.
Updates Surg. 2025 Sep 1. doi: 10.1007/s13304-025-02382-z.
Long-term survivors after pancreatic resection for PDAC are rare, constituting a specific subset of patients that remains poorly understood. This study aims to identify the clinic-pathological, molecular, and therapeutic factors for predicting long-term survival (LTS). A systematic review and random-effect meta-analysis were conducted. Inclusion criteria were PDAC histology, resected patients, studies reporting risk factors, and comparing two groups. The primary endpoint was to evaluate predictive factors for LTS in patients with PDAC who underwent surgery. Results were reported with the Mantel-Haenszel random effects model using Risk Ratio (RR) or Mean Difference (MD). Meta-regression analysis was used to clarify heterogeneity. Nineteen studies, involving a total of 5412 patients, were included: 1097 (20,3%) in group LTS and 4334 (79,7%) in group STS (short-term survivors). These factors were associated to LTS: small size (RR 1.53, 95% IC 1.14; 2.05); T1-T2 stage (RR 1.07, 95% IC 1.03; 1.11); N0 (RR 1.82, 95% IC 1.60; 2.09); AJCC Stage I (RR 2.28 95% IC 1.87; 2.79); low-grade G1-2 (RR 1.21, 95% IC 1.09; 1.34); R0 resection (RR 1.11, 95% IC 1.08; 1.13); low levels of CEA (MD - 4.41, 95% IC - 6.23; - 2.59) and Ca 19.9 (MD - 66.4, 95% IC: - 71.9; - 60.9); absence of perineural invasion (RR 0.93, 95% IC: 0.90; 0.96), lymph-vascular invasion (RR 0.87, 95% IC: 0.83; 0.91), venous invasion (RR 0.63, 95% IC: 0.48; 0.83) and perioperative transfusions (RR 0.56, 95% IC: 0.40; 0.79). Several factors are associated with an LTS. They can be considered reliable indicators for predicting tumor progression.
胰腺癌切除术后的长期存活者很少见,构成了一个仍未被充分了解的特定患者亚组。本研究旨在确定预测长期生存(LTS)的临床病理、分子和治疗因素。进行了一项系统评价和随机效应荟萃分析。纳入标准为胰腺癌组织学、接受手术的患者、报告危险因素并比较两组的研究。主要终点是评估接受手术的胰腺癌患者长期生存的预测因素。结果采用Mantel-Haenszel随机效应模型,以风险比(RR)或平均差(MD)报告。采用Meta回归分析来阐明异质性。纳入了19项研究,共涉及5412例患者:长期生存组1097例(20.3%),短期生存组4334例(79.7%)。这些因素与长期生存相关:肿瘤体积小(RR 1.53,95%CI 1.14;2.05);T1-T2期(RR 1.07,95%CI 1.03;1.11);N0(RR 1.82,95%CI 1.60;2.09);美国癌症联合委员会(AJCC)I期(RR 2.28,95%CI 1.87;2.79);低级别G1-2(RR 1.21,95%CI 1.09;1.34);R0切除(RR 1.11,95%CI 1.08;1.13);癌胚抗原(CEA)水平低(MD -4.41,95%CI -6.23;-2.59)和糖类抗原19-9(Ca 19.9)水平低(MD -66.4,95%CI:-71.9;-60.9);无神经周围侵犯(RR 0.93,95%CI:0.90;0.96)、无淋巴管侵犯(RR 0.87,95%CI:0.83;0.91)、无静脉侵犯(RR 0.63,95%CI:0.48;0.83)以及无围手术期输血(RR 0.56,95%CI:0.40;0.79)。有几个因素与长期生存相关。它们可被视为预测肿瘤进展的可靠指标。